Carriers of HLA-DRB1*04:05 have a better clinical response to abatacept in rheumatoid arthritis

Carriers of HLA-DRB1*04:05 have a better clinical response to abatacept in rheumatoid arthritis

Abstract HLA-DRB1 shared epitope risk alleles are the strongest genetic risk factors for rheumatoid arthritis (RA) and potential biomarkers for treatment response to biological disease-modifying antirheumatic drugs (bDMARDs). This study aimed to investigate the association between treatment response...

Full description

Bibliographic Details
Main Authors: Mariko Inoue, Yasuo Nagafuchi, Mineto Ota, Haruka Tsuchiya, Shoko Tateishi, Hiroko Kanda, Keishi Fujio
Format: Article
Language:English
Published: Nature Portfolio 2023-09-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-023-42324-6

Internet

https://doi.org/10.1038/s41598-023-42324-6

Similar Items